1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

AdvaMed Chair Nadim Yared Talks Challenges, Priorities

 
• By David Filmore

The AdvaMed chairman and CVRx CEO spoke to Medtech Insight from the floor of the Pennsylvania Convention Center at this year's MedTech Conference. The discussion focused on the industry's push for a breakthrough reimbursement pathway, the impact of US-China tariff wars and the industry's answer to challenges from grassroots patient groups on device safety, among other challenges and priorities.

Philadelphia, Pa. USA, Aug. 11, 2018: main entrance of the Pennsylvania Convention Center with police during the Philly Free Streets event.
The MedTech Conference was held this week at the Pennsylvania Convention Center in Philadelphia

AdvaMed is hopeful the Trump administration will propose a new reimbursement pathway by year's end that could supply temporary, automatic coverage to US FDA-designated breakthrough devices on the condition of data collection. That is among the issues discussed by AdvaMed Chairman and CVRx Inc. President and CEO Nadim Yared in a interview with Medtech Insight's editor David Filmore at the 2018 MedTech Conference in Philadelphia. Check out the interview in the video below.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

New EU Rules Limit Chinese Participation In Medtech Procurement

 
• By Amanda Maxwell

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

Guidance Details EU Approach On Medtech, AI Regulation Interplay

 
• By Amanda Maxwell

Overlapping clinical testing requirements and decision-making around significant changes to MDAI are among the tricky subjects that the new document explains.

UK MHRA Joins New Global Network For Safe Use Of AI In Healthcare

 
• By Natasha Barrow

The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.

More from Policy & Regulation

UK Trails NHS 10-Year Plan With Launch Imminent

 
• By Ashley Yeo

Healthcare product industries await publication of the NHS 10-Year Plan, due out the coming days, which will focus on health generally not just the NHS, UK health secretary Wes Streeting said during a final prelaunch event on 24 June.

New EU Rules Limit Chinese Participation In Medtech Procurement

 
• By Amanda Maxwell

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

Mexico’s New Procurement Rules Aim To Increase Healthcare Investment, But May Face Legal Trouble

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.